Nestled amid the lush countryside of New Zealand, where crisp mountain air drifts over pristine lakes and pastoral farms, a global benchmark in medicinal cannabis has taken root.
CANNFX, the premium brand of Ampyl Sciences, was founded with a visionary focus on providing patients globally with the highest quality NZ-grown pharmaceutical-grade medicinal cannabis. Every dried flower is cultivated indoors under strict controls, one carefully grown bud at a time.
Having just returned from picking up a shipment for export from a cultivator near one of the purest water springs in the southern hemisphere, founder and CEO Bastiaan Kramer reflects on how this trip represents the company’s mission. Providing premium cannabis flower from plant to patient.
New Zealand is known for its rigorous medicinal cannabis regulations. The country mandates tight pesticide controls, has the strictest microbial testing in the world and there is no irradiation. These are requirements that CANNFX has embedded into its DNA, and in collaboration with its cultivators, became the first company to successfully export NZ-grown medicinal cannabis flower to the EU and UK.
Behind the scenes, the company’s momentum is driven by its experienced leadership team. Directors Tina Jennen (Co-Founder) and Mohini Ha bring extensive guidance in governance, compliance, strategic development and international operations. Their leadership is instrumental in shaping CANNFX’s patient-focused, science-led expansion.
Building the Bridge: Supply Chain Mastery
The engine behind CANNFX’s global success is its expert navigation of international regulations, manufacturing compliance and logistical agility. From the outset, it recognized a critical gap in the industry. Cultivators excel at growing cannabis but face challenges navigating the complex regulatory and supply chain landscape for medicinal use. CANNFX addressed this by building a vast foundation necessary to successfully manage the plant-to-patient infrastructure.
Early in its journey, CANNFX established key and in some cases exclusive partnerships for European distribution, most notably with Cantourage in Germany and the UK. It also signed exclusive agreements with leading cultivators across New Zealand, aligned with GMP-certified manufacturers, and built global supply chains. This allows cultivators to focus on what they do best—growing premium flowers—while CANNFX manages the complex journey from harvest to healthcare.
The business model draws inspiration from Zespri, New Zealand’s world-renowned kiwifruit brand, whose headquarters lie just miles from CANNFX’s base. Much like Zespri, CANNFX empowers growers to focus on cultivating the best possible product while it takes the role of brand steward and global distributor, ensuring only premium products reach consumers.
It hasn’t always been plain sailing, however. CANNFX has had to navigate many issues throughout its journey, but it always faces each one as an opportunity for growth. “Where roads become difficult, we pave new ones” Bastiaan states optimistically.
Now, almost 6 years since inception, CANNFX works with eight manufacturers in five countries, receives premium flower from more than a dozen cultivators and its supply chain spans four continents.
Soul of the Product: Genetics, Terpenes, Prevention
CANNFX isn’t chasing every form of cannabis product. The company has taken a strategic stance to focus exclusively on medicinal cannabis flowers. With a market demand of nearly 80 percent for flowers, this decision enables the company to hone its expertise and deliver consistent quality and therapeutic value.
But it’s more than just choosing flowers over oils or tinctures. CANNFX invests in precision genetics and terpene science. All production occurs indoors, in controlled environments. This allows rigorous control over climate, nutrient regimes and microbial environments. One of the most important innovations has been a preventative approach to microbial mitigation. Instead of remediating issues at harvest, farms actively prevent mold and microbes from forming, allowing plants to channel their energy into producing larger flowers with optimal THC and terpene levels. This is quality, rooted in science and nurtured in nature.
The upshot? Consistent cannabinoid profiles with richer terpene expressions that give patients and providers assurance in quality, efficacy and therapeutic experience. In markets like the EU and Australia, where standards are especially stringent, this precision places CANNFX firmly ahead of the competition.
Scaling Up: Partnerships and Expansion
Since its inception, CANNFX has followed a focused and ambitious growth strategy. In 2020, it launched its brand, secured distribution in Germany and the UK, and signed exclusive cultivation contracts—laying the foundation for international expansion. Between 2021 and 2023, it expanded its supply chains, partnered with GMP-certified manufacturers and streamlined export logistics to support compliant global distribution.
The momentum continued in 2024 with the addition of four New Zealand cultivators and two new international supply chains. Today, CANNFX operates in multiple countries with a combined population exceeding 160 million, with plans in place to expand into three more markets, representing an additional 100 million people in 2026.
While the current focus remains on dried flowers, CANNFX is well-positioned to expand into oils, tinctures and other product forms as regulations evolve.
Implementing this strategic growth is Bastiaan, whose professional journey didn’t begin in cannabis. His career was built in global corporations during a 15-year career in the Netherlands, primarily in banking and IT, but also logistics and regulatory affairs—fields that demanded expertise in navigating complex systems, aligning with government and managing international compliance. When the opportunity to establish Ampyl Sciences emerged in 2019, Bastiaan brought together his foundation of global business acumen and a passion for building ventures that create meaningful societal impact. Medicinal cannabis became his next frontier.
CANNFX operates on a foundation of trust, transparency and accountability, values that extend outward to every partner and stakeholder.
“We have a very open, transparent relationship within the company, and we share that with our outside partners. We say what we do, and we do what we say,” he adds. In this industry, that speaks volumes.
The result is a values-driven, high-integrity organization that delivers consistency and reliability across every step of the international medicinal cannabis supply chain.
Seeds for the Future
CANNFX’s future is grounded in discipline and fueled by ambition. It has already integrated new cultivators and activated additional global supply routes. New legal markets are being evaluated and will be supported by active strategic planning.
Its north star is upholding patient-first standards without compromise. In every market it enters, CANNFX brings premium cannabis along with its trademark quality, safety and trust. This isn’t just a business success story. CANNFX demonstrates how environmental integrity, regulatory rigor and ethical leadership can converge to raise the global standard for medicinal cannabis.
“CANNFX is moving into our next phase of growth and we are excited about the new collaborative opportunities this will create,” Bastiaan finishes.
In a market often characterized by inconsistent quality and regulatory flux, CANNFX offers dependability. Rooted in New Zealand’s pristine natural ecosystem, structured around pharmaceutical standards and built with a care-first mindset, it is setting a new industry benchmark.
This is why CANNFX has been voted Medicinal Cannabis Company – APAC Region 2025.
CANNFX, the premium brand of Ampyl Sciences, was founded with a visionary focus on providing patients globally with the highest quality NZ-grown pharmaceutical-grade medicinal cannabis. Every dried flower is cultivated indoors under strict controls, one carefully grown bud at a time.
Where roads become difficult, we pave new ones
New Zealand is known for its rigorous medicinal cannabis regulations. The country mandates tight pesticide controls, has the strictest microbial testing in the world and there is no irradiation. These are requirements that CANNFX has embedded into its DNA, and in collaboration with its cultivators, became the first company to successfully export NZ-grown medicinal cannabis flower to the EU and UK.
Behind the scenes, the company’s momentum is driven by its experienced leadership team. Directors Tina Jennen (Co-Founder) and Mohini Ha bring extensive guidance in governance, compliance, strategic development and international operations. Their leadership is instrumental in shaping CANNFX’s patient-focused, science-led expansion.Building the Bridge: Supply Chain Mastery
The engine behind CANNFX’s global success is its expert navigation of international regulations, manufacturing compliance and logistical agility. From the outset, it recognized a critical gap in the industry. Cultivators excel at growing cannabis but face challenges navigating the complex regulatory and supply chain landscape for medicinal use. CANNFX addressed this by building a vast foundation necessary to successfully manage the plant-to-patient infrastructure.
Early in its journey, CANNFX established key and in some cases exclusive partnerships for European distribution, most notably with Cantourage in Germany and the UK. It also signed exclusive agreements with leading cultivators across New Zealand, aligned with GMP-certified manufacturers, and built global supply chains. This allows cultivators to focus on what they do best—growing premium flowers—while CANNFX manages the complex journey from harvest to healthcare.
The business model draws inspiration from Zespri, New Zealand’s world-renowned kiwifruit brand, whose headquarters lie just miles from CANNFX’s base. Much like Zespri, CANNFX empowers growers to focus on cultivating the best possible product while it takes the role of brand steward and global distributor, ensuring only premium products reach consumers.
It hasn’t always been plain sailing, however. CANNFX has had to navigate many issues throughout its journey, but it always faces each one as an opportunity for growth. “Where roads become difficult, we pave new ones” Bastiaan states optimistically.
Now, almost 6 years since inception, CANNFX works with eight manufacturers in five countries, receives premium flower from more than a dozen cultivators and its supply chain spans four continents.
Soul of the Product: Genetics, Terpenes, Prevention
CANNFX isn’t chasing every form of cannabis product. The company has taken a strategic stance to focus exclusively on medicinal cannabis flowers. With a market demand of nearly 80 percent for flowers, this decision enables the company to hone its expertise and deliver consistent quality and therapeutic value.
But it’s more than just choosing flowers over oils or tinctures. CANNFX invests in precision genetics and terpene science. All production occurs indoors, in controlled environments. This allows rigorous control over climate, nutrient regimes and microbial environments. One of the most important innovations has been a preventative approach to microbial mitigation. Instead of remediating issues at harvest, farms actively prevent mold and microbes from forming, allowing plants to channel their energy into producing larger flowers with optimal THC and terpene levels. This is quality, rooted in science and nurtured in nature.The upshot? Consistent cannabinoid profiles with richer terpene expressions that give patients and providers assurance in quality, efficacy and therapeutic experience. In markets like the EU and Australia, where standards are especially stringent, this precision places CANNFX firmly ahead of the competition.
Scaling Up: Partnerships and Expansion
Since its inception, CANNFX has followed a focused and ambitious growth strategy. In 2020, it launched its brand, secured distribution in Germany and the UK, and signed exclusive cultivation contracts—laying the foundation for international expansion. Between 2021 and 2023, it expanded its supply chains, partnered with GMP-certified manufacturers and streamlined export logistics to support compliant global distribution.
The momentum continued in 2024 with the addition of four New Zealand cultivators and two new international supply chains. Today, CANNFX operates in multiple countries with a combined population exceeding 160 million, with plans in place to expand into three more markets, representing an additional 100 million people in 2026.
While the current focus remains on dried flowers, CANNFX is well-positioned to expand into oils, tinctures and other product forms as regulations evolve.Implementing this strategic growth is Bastiaan, whose professional journey didn’t begin in cannabis. His career was built in global corporations during a 15-year career in the Netherlands, primarily in banking and IT, but also logistics and regulatory affairs—fields that demanded expertise in navigating complex systems, aligning with government and managing international compliance. When the opportunity to establish Ampyl Sciences emerged in 2019, Bastiaan brought together his foundation of global business acumen and a passion for building ventures that create meaningful societal impact. Medicinal cannabis became his next frontier.
-
We have a very open, transparent relationship within the company, and we share that with our outside partners. We say what we do, and we do what we say
CANNFX operates on a foundation of trust, transparency and accountability, values that extend outward to every partner and stakeholder.
“We have a very open, transparent relationship within the company, and we share that with our outside partners. We say what we do, and we do what we say,” he adds. In this industry, that speaks volumes.
The result is a values-driven, high-integrity organization that delivers consistency and reliability across every step of the international medicinal cannabis supply chain.
Seeds for the Future
CANNFX’s future is grounded in discipline and fueled by ambition. It has already integrated new cultivators and activated additional global supply routes. New legal markets are being evaluated and will be supported by active strategic planning.
Its north star is upholding patient-first standards without compromise. In every market it enters, CANNFX brings premium cannabis along with its trademark quality, safety and trust. This isn’t just a business success story. CANNFX demonstrates how environmental integrity, regulatory rigor and ethical leadership can converge to raise the global standard for medicinal cannabis.“CANNFX is moving into our next phase of growth and we are excited about the new collaborative opportunities this will create,” Bastiaan finishes.
In a market often characterized by inconsistent quality and regulatory flux, CANNFX offers dependability. Rooted in New Zealand’s pristine natural ecosystem, structured around pharmaceutical standards and built with a care-first mindset, it is setting a new industry benchmark.
This is why CANNFX has been voted Medicinal Cannabis Company – APAC Region 2025.
